Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Orgenesis Inc. (NASDAQ:ORGS ) Q4 2022 Earnings Conference Call March 21, 2023 11:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company William Jordan - TSA Investment Steve Waite - Gilder Publishing Operator Greetings. Welcome to the Orgenesis 2022 Year End Business Update Conference Call.

Orgenesis Inc. (ORGS) Q4 2022 Earnings Call Transcript

Rapid g rowth r eflect s p rogress of POCare Platform

Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022

GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, March 21, 2023, to discuss the company's corporate progress and other developments.

Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announces the signing of a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis).

Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California

GERMANTOWN, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced the closing of its previously announced Registered Direct Offering of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. The completion of the transaction has resulted in aggregate gross proceeds to the Company of approximately $3.7 million before deducting the placement agent's fees and other offering expenses payable by the Company. The warrants have an exercise price of $1.90 per share, are exercisable immediately and will expire five years following the date of issuance.

Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering

GERMANTOWN, Md., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Orgenesis, Inc. (Nasdaq: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,947,368 common stock and warrants to purchase up to 973,684 shares of common stock at a purchase price of $1.90 per share of common stock and accompanying warrants in a registered direct offering. The aggregate gross proceeds to the Company are expected to be approximately $3.7 million before deducting the placement agent's fees and other offering expenses payable by the Company. The warrants have an exercise price of $1.90 per share, are exercisable immediately and will expire five years following the date of issuance. The warrants have an alternate cashless option (beginning on or after the earlier of (a) the thirty-day anniversary of the date of the purchase agreement and (b) the date on which the aggregate composite trading volume of our common stock following the public announcement of the pricing terms exceeds 13,600,000 shares), to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise and (y) 1.0.

Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering

Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).

New Dimensions Trading Discloses Large Position in ORGS / Orgenesis

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr.

Orgenesis (ORGS) Q3 2022 Earnings Call Transcript

Secures up to $50 Million of Funding from Metalmark Capital Partners  Expected to Accelerate Rollout of Point-of-Care Services

Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company's corporate progress and other developments.

Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

GERMANTOWN, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced an investment partnership whereby Metalmark has agreed to make a growth investment of up to $50 million in Orgenesis' US-based point of care services subsidiary, Morgenesis LLC (“Morgenesis”). The investment will be made at a pre-money valuation of $125 million, subject to customary adjustments, and will consist of an upfront investment of $30 million and two future investments of $10 million each, subject to the achievement of certain milestones. The initial investment of $30 million will consist of $20 million in cash and conversion of the convertible loan Metalmark previously provided to Morgenesis in August 2022.

Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services

Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Operator Good day, ladies and gentlemen, and welcome to the Orgenesis Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, David Waldman from Investor Relations.

Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for Orgenesis (NASDAQ:ORGS)' point of care (POCare) services business for treating patients.

Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform

Secures Funding from Metalmark Capital Partners to Drive Growth

Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company's corporate progress and other developments.

Orgenesis Schedules Second Quarter 2022 Business Update Conference Call

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and expects to benefit from recurring revenue streams from long-term contracts for the next two to three years. This follows the building of a robust network of POCare centers across Europe, Asia and the Middle East and the implementation of its POCare supply strategy in the US, the company said.

Orgenesis enters second phase of POCare Platform rollout; sees recurring revenues from long-term contracts for the next 2-3 years

GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today provided a business update for first quarter ended March 31, 2022.

Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports cutting-edge science and technology in order to create new market opportunities. The consortium members include MIDA Biotech B.V.

Orgenesis says consortium led by its MIDA Biotech subsidiary wins 4 million euro grant supporting cutting edge technology

Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial Intelligence (AI) Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial Intelligence (AI)

Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8 million before deducting related offering expenses. The company said the placement will see the sale of 4,933,333 shares of the company's common stock at a purchase price of $3.00 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $4.50 per share.

Orgenesis inks agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8M

Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript

Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial year, Orgenesis (NASDAQ:ORGS) reported $35.5 million in revenue compared to $7.7 million in the previous year.

Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globe

Orgenesis to host conference call today at 12:00 PM ET Orgenesis to host conference call today at 12:00 PM ET

Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has been reached by completing the placement of an Orgenesis (NASDAQ:ORGS) Mobile Processing Unit and Lab (OMPUL) on site.

Orgenesis achieves latest milestone in its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

GERMANTOWN, Md., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announces it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús (“Hospital”) in Madrid, Spain.

News for Orgenesis Stock (ORGS)